Overview
WARNING: As this organisation lists one or more EP accredited lobbyists, it may not be probable that its lobbying costs are lower than €10,000.
Lobbying Costs
10,000€ - 24,999€
Financial year: Jan 2020 - Dec 2020
Lobbyists (Full time equivalent)
1.5 Fte (6)
Lobbyists with EP accreditation
0
High-level Commission meetings
2
Lobbying Costs over the years
-
Info
European AIDS Treatment Group (EATG)
EU Transparency Register
49959188061-85 First registered on 13 Feb 2012
Goals / Remit
For 2020-2025, EATG’s mission is:
Equitable, speedy and sustainable access to:
• effective treatments and holistic care for all people living with HIV
• effective prevention and diagnosis for all communities affected by HIV
EATG has 3 Programme Areas:
-Quality of Life to engage, inform and empower all people living with and affected by HIV in improving their health-related quality of life.
- Combination Prevention to engage, inform and empower all people living with and affected by HIV in increasing the usage of HIV, viral hepatitis, TB and STI combination prevention and diagnostic strategies in affected communities.
-Partners in Science - To engage, inform and empower all people living with and affected by HIV in ensuring that ongoing research continues to yield best quality new HIV, viral hepatitis, TB and STI diagnostics, medicines, medical devices, and care, as well as progress towards cure.Main EU files targeted
- EU Pharmaceutical Strategy - Timely patient access to affordable medicines : consultation on the roadmap and strategy: EATG submission and via European Public Health Alliance as members.
- EU4Health Programme: input into WP 2021 and 2022 via EC webinar and contribution to HIV Outcomes, CSF on HIV,TB and Hep and ACHIEVE Coalition
- Establishment of the European Health Data Space: contribution the debate by the EmERGE closing meeting (EC funded project), submission to EC consultation, speaker at European Public Health Alliance meeting
- Cancer mission, EU Beating Cancer plan and EU4health WP 2022: input regarding virus caused cancers as EATG and as part of the ACHIEVE coalition for the elimination of viral hepatitis
- EU drug policy strategy and action plan 2021-2025 and action plan: contribution via the EU Civil Society Forum on Drugs
- Proposal for a regulation of the European Parliament and of the Council on the European Union Drugs Agency: contribution via the EU Civil Society Forum on Drugs
- ECDC HIV Dublin monitoring: input to advisory group and EATG/AAE/ECDC survey on stigma
- Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices: monitor implementation and request for clarifications regarding rapid diagnostic test and use by lay provider
Previous input/submissions:
- COMMISSION STAFF WORKING DOCUMENT SWD(2018) 387 final on Combatting HIV/AIDS, viral hepatitis and tuberculosis in the European Union and neighbouring countries - State of play, policy instruments and good practices
- Submission to EMA Consultation on the Role of big data for evaluation and supervision of medicines in the EU
- submission to EU Drugs Strategy 2013-20 – evaluation consultation(December 2019-Feb 2020);
- submission to EU Drugs Agenda and Action Plan consultation in June-July 2020
- ECDC: Public health guidance on HIV, hepatitis B and C testing in the EU/EEA: input as expert, 2018Address
Head Office
Mettmanner Strasse, 24-26
Düsseldorf 40233
GERMANYEU Office
Avenue des Arts 56-4c
Brussels 1000
BELGIUMWebsite
-
People
Total lobbyists declared
6
Employment time Lobbyists 25% 6 Lobbyists (Full time equivalent)
1.5
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
0 accreditations were / are live (in bold) for the selected state of 13 May 2022
Name Start date End Date Chiara LONGHI 14 Mar 2024 13 Mar 2025 Ann Isabelle von Lingen 23 Mar 2024 02 Oct 2024 Ms Ann Isabelle von Lingen 23 Mar 2024 15 Apr 2024 Ms Chiara LONGHI 14 Mar 2024 15 Apr 2024 Mr Pieter VANHOLDER 15 May 2020 01 Jun 2021 Ms Ann Isabelle von Lingen 13 May 2020 13 May 2021 Mr Pierre VARASI 20 Feb 2020 20 Feb 2021 Ms Marina COGNEE 20 Feb 2020 20 Feb 2021 Mr Bojan CIGAN 20 Feb 2020 20 Feb 2021 Giorgio BARBARESCHI 20 Feb 2020 20 Feb 2021 Mr Pieter VANHOLDER 18 Apr 2019 01 May 2020 Ms Ann Isabelle von Lingen 04 Apr 2019 04 Apr 2020 Ms Fiona GREENHALGH 04 Apr 2019 12 Feb 2020 Ms Ann Isabelle von Lingen 21 Feb 2017 17 Feb 2018 Complementary Information
We are a voluntary organisation with over 150 members from over 45 countries within and outside Europe.
Our full-time Programme Manager works approx. 1/3 of her time on transparency register activities.Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Non-governmental organisations, platforms and networks and similar
-
Networking
Affiliation
EU Civil Society Forum (CSF) on HIV , TB and Hepatitis
EU Civil Society Forum on Drugs
WHO Regional Coordination Committee on HIV, TB and Hep
AIDS Action Europe;
European Public Health Alliance (EPHA);
European Forum for Good Clinical Practice (EFGCP)
European Patient Forum (EPF)
Platform for Cooperation with undocumented migrants (PICUM)
ILGA – Europe
PHILEA - Philanthropy Europe Association
ESWA - European Sex Workers Rights AllianceMember organisations
None declared
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Jan 2020 - Dec 2020
Lobbying costs for closed financial year
10,000€ - 24,999€
Major contributions in closed year
None declared
Intermediaries for closed year
None declaredIntermediaries for current year
None declaredClosed year Costs
10,000€ - 24,999€
Other financial info
None declared
-
EU Structures
Groups (European Commission)
Commission expert group - Civil Society Forum on Drugs#E02681#https://ec.europa.eu/transparency/expert-groups-register/screen/expert-groups/consult?groupID=2681 #Member #C#Civil society#Sub-group on Relations with International Institutions
Groups (European Parliament)
LGTBI#EU Civil Society Forum on Drugs
Communication activities
EU Civil Society forum on HIV, TB and Hepatitis coordination with AAE, EHRA, Correlations, TBEC. EATG acts as secretariat together with AAE.
HIVACAR: The project aims to change the current paradigm of HIV treatment by obtaining a functional cure for HIV thanks to effectively targeting residual virus replication and viral reservoirs.
EHVA: This project Project aims: To develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines. The MVP includes four components: 1) Discovery, 2) Immune Profiling, 3) Data Management, Integration and Down-Selection, and 4) Clinical Trials.
RBDCOV - RBD Dimer recombinant protein vaccine against SARSCoV2 This project aims to test the efficacy, tolerability and safety of HIPRA's recombinant COVID-19 vaccine in children (including adolescents) and immunocompromised individuals.
EU-PEARL – EU Patient-Centric Clinical Trial Platform - This project has the ambition of transforming the current approach of conducting single-compound clinical trials into the use of cross-company Integrated Research Platforms (IRPs), taking into consideration both patients’ interests and the opportunities from novel molecules for addressing medical needs.
EATRIS+ - Flagship in Personalised Medicines - The overarching aim of EATRIS-Plus is to support the long-term sustainability (LTS) of EATRIS by delivering innovative scientific tools to the research community, strengthening the infrastructure’s financial model and reinforcing EATRIS leadership in the European Research Area (ERA), particularly in the field of Personalised Medicine (PM) research and development.
PROMs in HIV Research and Development: The purpose of the work is to describe the current use of PROMs in HIV research and development Results were presented and discussed during an EATG-curated session at the EACS 2021 conference.
https://www.eatg.org/publications/proms-in-hiv-research-and-development-analysis-of-community-needs-and-engagement/
From March 2020 to January 2021, EATG documented the impact of the disruption caused by the SARS-COV2 pandemic on people living with or most affected by HIV and solutions found to mitigate it, including at community level. EATG published 6 bulletins, organised mutual learning e-meetings on HIV self-testing, ensuring continuity in sexual health services, COVID-19 vaccines, adaptation of services at community level: https://linktr.ee/eatgcovid19
The HIV and Mental Health project aimed to explore the existing knowledge about the interplay of mental health, well-being and HIV and translate it into practical recommendations for both community organisations and healthcare professionals in the European context. https://www.eatg.org/publications/survey-report-mental-health-of-people-living-with-hiv-and-staff-of-organisations-working-in-the-field-of-hiv-in-the-who-european-region/
40 years of HIV/AIDS: Stigma & Discrimination and the impact on Mental Health:
https://www.eatg.org/campaigns/wad-2021-40-years-of-hiv-aids-stigma-discrimination-and-the-impact-on-mental-health/
EATG, together with ECDC and AAE coordinated and launched the first ever European-wide HIV stigma survey. Results will be published later in 2022.
https://www.eatg.org/news/the-first-ever-european-wide-hiv-stigma-survey-is-launched/
HIV and eHealth: Opportunities and Challenges for People Living with and Affected by HIV:
https://www.eatg.org/publications/hiv-and-ehealth-opportunities-and-challenges-for-people-living-with-and-affected-by-hiv/
EATG endorsed a series of letters and statements touching upon EU policies on health, access, funding, human rights etc.
https://www.eatg.org/endorsements-and-sign-ons/Other activities
Achievements:
EATG has been at the forefront of community involvement in treatment development in HIV and co-infections. Our models of community involvement are shared with patient organisations beyond the HIV and co-infections field. EATG has been leading on innovative techniques such as biomedical prevention and HIV cure research.
EATG has been actively involved in setting up the EU Civil Society Forum on HIV, hepatitis and TB. Currently we are playing a leading role in the reform of the CSF.
In 1997 EATG created the European Community Advisory Board (ECAB) to address key science and policy issues related to HIV and its main co-infections like hepatitis C or tuberculosis. Today and in the coming years, these ECABs will remain one of EATG’s core activities. This model of high-level scientific platform has been copied by other national and international community groups and networks (e.g. Portuguese CAB, EECA CAB, TB CAB, Positive Council Switzerland etc.)
Via our ‘Sitges’ meetings, EATG has driven the community input in HCV cure development.
EATG provides capacity building to different stakeholders, thus supporting better networking (especially in Central and Eastern Europe), increased capacity of people living with HIV and health care providers, but also – via follow up activities – direct involvement of these people in new scientific and policy activities.
Population(s) served:
The European AIDS Treatment Group (EATG) is a patient-led NGO that advocates for the rights and interests of people living with or affected by HIV/ AIDS and related co-infections within the WHO Europe region. It is a network of more than 150 members from 45 countries in Europe. Our members are PLHIV and representatives of different communities affected by HIV/AIDS and co-infections. EATG represents the diversity of more than 2.3 million people living with HIV in Europe as well as those affected by HIV/AIDS and co-infections.
Our members are representatives of different communities affected by HIV/AIDS in Europe. Our members are expert patients and treatment advocates coming from the WHO European region continuously working together to end the epidemic by advancing research on HIV/AIDS, broadening access to treatment, training/mentoring new HIV/AIDS advocates and ensuring that the patient Community is a permanent and highly-recognised voice in the research arena.
EATG has close links with groups and organisations within the area of sex work, drug use, MSM, migrants, prisoners etc. Our work is also in close collaboration with organisations that work on related topics such as vaccine development, prevention, liver disease, sexual health or human rights issues such as stigma and discrimination.
Involvement of people living with HIV :
EATG is a membership driven organisation. Our members are all members of the General Assembly (GA), the highest decision-making body of the EATG. A major part of our members are people living with HIV. The GA is called at least annually by the Board of Directors (BoD). The GA elects the members of the BoD and other bodies. Directors are elected for a period of two years.
HIV positive members are also represented within each part of the structure (selected via democratic systems): Programme Chairs; BoD members, staff and other internal positions. EATG has 3 Programme Areas: Quality of Life, Combination Prevention and Partners in Science. Members become active within one or more of the Programmes, as part of designated Programme Committees or ad hoc task groups. EATG regularly organises consultations with its members and other groups. We actively support the GIPA principle.
Members are the main drivers of our strategic development. With support from the office members, they draft our long-term strategy, set priorities etc. We have many HIV-positive members involved as representatives within different structures and positions such as steering committees, scientific committees, and advisory boards.- Meetings
Meetings
2 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 22 Jul 2019 Location Brussels Subject Access to medicines Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Alina Timofte (Cabinet member)
- Arunas Vinciunas (Cabinet member)
- Vytenis Andriukaitis (Commissioner)
Other Lobbyists -
Date 28 Nov 2016 Location Brussels Subject EU and NGOs action on HIV, TB and Hepatitis Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Vytenis Andriukaitis (Commissioner)
- Paula Duarte Gaspar (Cabinet member)
Other Lobbyists
- Meetings